Probiotic-associated bifidobacterium septic prosthetic joint arthritis

Infectious Diseases in Clinical Practice

Volumn 22, Issue 4, 2014, Pages

  Bush, Larry M ^a,b,c,d   De Almeida, Kleper N F ^b,c   Martin, Gregory ^c   Perez, Maria T ^c  

^a FLORIDA ATLANTIC UNIVERSITY   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c JFK Medical Center   (United States)

^d Fourth Quadrant Partners   (United States)

Author keywords

Bifidobacteria; Probiotic; Septic prosthetic joint arthritis

Indexed keywords

ERTAPENEM; PROBIOTIC AGENT; TOBRAMYCIN; VANCOMYCIN;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; ASPIRATION; BACTERIAL INFECTION; BACTERIUM CULTURE; BACTERIUM ISOLATION; BIFIDOBACTERIUM; CASE REPORT; CEMENT SPACER; ERYTHEMA; FEMALE; FEVER; HIP DISLOCATION; HUMAN; LEUKOCYTE; MALAISE; MEDICAL DEVICE COMPLICATION; METAL ON METAL JOINT PROSTHESIS; METALLOSIS; MIDDLE AGED; OSTEOARTHRITIS; POLYMORPHONUCLEAR CELL; POSTOPERATIVE PAIN; REOPERATION; SEPSIS; SYNOVIAL FLUID; TOTAL HIP PROSTHESIS;

EID: 84905565181     PISSN: 10569103     EISSN: 15369943     Source Type: Journal    
DOI: 10.1097/IPC.0b013e318291c88e     Document Type: Article

References (18)

1. The probiotic market: Ingredients, Supplements, Foods. BCC Research; June 2011: Report Code FODO35C.
2. Sanders ME. Probiotics: definition, sources, selection and uses. Clin Infect Dis. 2008;46: S58-S61.
3. Hempel S, Newberry SJ, Maher AR, et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA. 2012;307: 1959-1969.
4. Johnstone BC, Ma SY, Goldenberg JZ, et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea. Ann Intern Med. 2012;157: 878-888.
5. Floch MH, Montrose DC. Use of probiotics in human: an analysis of the literature. Gastroenterol Clin North Am. 2005;34: 547-570.
6. Goldin BR, Gorbach SL. Clinical indications for probiotics: an overview. Clin Infect Dis. 2008;46: S96-S100.
7. Tamayo C. Clinical research on probiotics: the interface between science and regulation. Clin Infect Dis. 2008;46: S101-S103.
8. Vanderhoof JA, Young R. Probiotics in the United States. Clin Infect Dis. 2008;46: S67-S72.
9. Burdock GA. Dietary supplements and lessons to be learned from GRAS. Regul Toxicol Pharmacol. 2000;31: 68-76.
10. Snydman DR. The safety of probiotics. Clin Infect Dis. 2008;46: S104-S111.
11. Gaskins HR, Croix JA, Nakamura N, et al. Impact of intestinal microbiota on the development of mucosal defense. Clin Infect Dis. 2008;46: S80-S86.
12. Bourne KA, Beebe JL, Lue YA, et al. Bacteremia due to Bifidobacterium, Eubacterium or Lactobacillus; twenty-one cases and review of the literature. Yale J Biol Med. 1978;51: 505-512.
13. Brook I, Frazier EH. Significant recovery of nonsporulating anaerobic rods from clinical specimens. Clin Infect Dis. 1993;16: 476-480.
14. Salminen MK. Lactobacillus Bacteremia, with Special Focus on the Safety of Probiotic Lactobacillus rhamnosus GG (Doctoral Dissertation). Helsinki: University of Helsinki; 2006.
15. Cassone M, Serra P, Mondello F, et al. Outbreak of Saccharomyces cerevisiae subtype boulardi fungemia in patients neighboring those treated with a probiotic preparation of the organism. J Clin Microbiol. 2003;41: 5340-5343.
16. Hoyles L, Inganas E, Falsen F, et al. Bifidobacterium scardovii sp. nov., from human sources. Int J Syst Bacteriol. 2002;52: 995-999.
17. Hoellman DB, Kelly LM, Credito K, et al. In vitro antianaerobic activity of ertapenem (MK-0826) compared to seven other compounds. Antimicrob Agents Chemother. 2002;46: 220-224.
18. Hempel S, Newberry S, Ruelaz A, et al. Safety of Probiotics to Reduce Risk and Prevent or Treat Disease. Evidence Report/Technology Assessment 200. (Prepared by the Southern California Evidence-based Practice Center under Contract No. 290-2007-10062-I) AHRQ Publication No. 11-E007. Rockville, MD: Agency for Healthcare Research and Quality; 2011. Available at: http: //www.ahrq.gov/clinic/ tp/probiotictp.htm.